A new study in mice looks at how activating healthy brown fat could help promote weight loss and protect against obesity.

Every investor just wants to find the perfect stock – but finding the shares that check every box can be a challenge. The ...

Incyte says the firm it is acquiring has new drug candidates representing multibillion-dollar revenue opportunities.

The average one-year price target for FibroGen (NasdaqGS:FGEN) has been revised to 1.78 / share. This is an increase of 40.00 ...

The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of ...

The Producer service offers customers a second option for accessing Asimov's technology for the cell and gene therapy ...

CEO Hervé Hoppenot said Tuesday on an investor call that Escient Pharmaceuticals’ two lead assets “address large populations ...

XC001 is designed to transiently grow new blood vessels to restore blood flow in the heart. It contains alternative splicing of the three isoforms of VEGF-A, which sets it apart from past attempts at ...

SCIENTISTS say they are onto a “promising” new treatment for leukaemia blood cancer which has not seen major progress for ...

The acquisition will give Incyte two dermatology drugs currently being investigated for several inflammatory skin diseases.

Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the ...